Your browser is no longer supported. Please, upgrade your browser.
Settings
APVO [NASD]
Aptevo Therapeutics Inc.
Index- P/E- EPS (ttm)-6.82 Insider Own5.29% Shs Outstand4.89M Perf Week-46.21%
Market Cap39.37M Forward P/E- EPS next Y-4.23 Insider Trans-85.59% Shs Float4.64M Perf Month-54.88%
Income-30.00M PEG- EPS next Q-1.10 Inst Own52.70% Short Float1.88% Perf Quarter-61.27%
Sales11.00M P/S3.58 EPS this Y38.20% Inst Trans-11.73% Short Ratio0.03 Perf Half Y-72.70%
Book/sh1.49 P/B4.72 EPS next Y8.50% ROA-45.40% Target Price52.50 Perf Year-84.71%
Cash/sh9.30 P/C0.76 EPS next 5Y- ROE-242.30% 52W Range6.38 - 47.98 Perf YTD-80.82%
Dividend- P/FCF- EPS past 5Y26.00% ROI- 52W High-85.35% Beta6.84
Dividend %- Quick Ratio- Sales past 5Y-33.70% Gross Margin- 52W Low10.19% ATR2.42
Employees58 Current Ratio1.80 Sales Q/Q106.70% Oper. Margin- RSI (14)38.86 Volatility18.99% 24.35%
OptionableNo Debt/Eq2.08 EPS Q/Q32.70% Profit Margin- Rel Volume0.19 Prev Close8.04
ShortableYes LT Debt/Eq0.55 Earnings- Payout- Avg Volume3.37M Price7.03
Recom2.00 SMA20-38.47% SMA50-48.71% SMA200-67.40% Volume651,865 Change-12.56%
Nov-05-18Initiated Ladenburg Thalmann Buy
Oct-05-17Resumed Piper Jaffray Overweight $6
Nov-23-21 08:05AM  
07:59AM  
Nov-15-21 08:05AM  
Nov-12-21 08:05AM  
Nov-11-21 04:45PM  
08:30AM  
Nov-02-21 09:00AM  
Oct-27-21 08:05AM  
Oct-26-21 08:05AM  
Sep-28-21 08:05AM  
Aug-17-21 08:05AM  
Aug-12-21 08:05AM  
Jul-16-21 08:05AM  
Jun-29-21 08:05AM  
May-27-21 09:00AM  
May-26-21 09:32AM  
09:00AM  
May-17-21 06:00AM  
May-11-21 09:00AM  
Apr-09-21 09:00AM  
Mar-31-21 08:00AM  
Feb-09-21 07:30PM  
Jan-11-21 08:00AM  
Jan-06-21 12:00PM  
Dec-19-20 01:45PM  
Dec-02-20 08:00AM  
Nov-20-20 07:37AM  
Nov-19-20 04:15PM  
Nov-16-20 08:00AM  
Nov-10-20 08:40AM  
Nov-09-20 09:00AM  
06:00AM  
Nov-08-20 11:15PM  
Nov-03-20 09:00AM  
Sep-01-20 09:00AM  
Aug-14-20 09:00AM  
Aug-06-20 09:00AM  
Jul-21-20 09:00AM  
Jun-30-20 12:00PM  
11:30AM  
Jun-29-20 09:00AM  
Jun-25-20 09:00AM  
Jun-10-20 09:00AM  
May-13-20 09:00AM  
Apr-14-20 09:00AM  
Mar-25-20 09:00AM  
Mar-16-20 09:00AM  
Feb-28-20 09:05AM  
08:59AM  
Jan-30-20 09:00AM  
Jan-13-20 08:00AM  
Dec-19-19 03:50PM  
Dec-06-19 09:00AM  
Nov-12-19 09:00AM  
Nov-08-19 09:00AM  
Nov-07-19 09:00AM  
Oct-04-19 07:32AM  
Oct-03-19 04:02PM  
04:02PM  
Sep-19-19 09:00AM  
Aug-09-19 09:00AM  
Aug-07-19 09:02AM  
Jul-25-19 04:32PM  
Jun-25-19 09:00AM  
May-09-19 09:00AM  
Apr-29-19 10:21AM  
Apr-26-19 08:31AM  
Apr-15-19 09:00AM  
Apr-11-19 12:26PM  
Apr-02-19 09:02AM  
Mar-25-19 09:02AM  
Mar-20-19 09:02AM  
Mar-18-19 09:00AM  
Mar-14-19 10:28AM  
Mar-07-19 09:13AM  
Mar-06-19 04:37PM  
Jan-07-19 08:30AM  
Jan-03-19 09:02AM  
Dec-21-18 09:00AM  
Dec-20-18 12:57PM  
Dec-13-18 09:02AM  
Dec-11-18 07:20AM  
Nov-20-18 09:00AM  
Nov-14-18 04:02PM  
Nov-09-18 12:00AM  
Oct-24-18 09:00AM  
Oct-10-18 08:40AM  
Sep-25-18 11:29AM  
Sep-05-18 11:36AM  
Aug-31-18 02:46PM  
Aug-09-18 09:00AM  
Aug-07-18 09:00AM  
Aug-06-18 08:10AM  
May-29-18 09:00AM  
May-15-18 07:40AM  
May-10-18 09:00AM  
May-08-18 09:02AM  
May-01-18 09:00AM  
Apr-30-18 07:50AM  
Apr-20-18 08:35PM  
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1/1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It is also developing APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer; and other pre-clinical development stage therapeutics focused on hematologic and solid tumors. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TANG KEVIN CExit FilingNov 23Sale11.25921,33610,368,2360Nov 26 01:02 PM
TANG KEVIN C10% OwnerNov 22Sale7.03255,3311,795,987921,336Nov 22 05:26 PM
TANG KEVIN C10% OwnerNov 19Sale7.59213,8001,622,8671,176,667Nov 22 05:26 PM
TANG KEVIN C10% OwnerNov 18Sale8.34369,5333,081,5571,390,467Nov 22 05:26 PM